The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
With standout ADC and t-cell engager response data across hard-to-treat cancers
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Highlighting KEYTRUDA & expanding cancer pipeline
Paves way for CNS cancer test rollout
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
